"Human Trial: Experimental Therapy Grows New Livers from Lymph Nodes"

Biotech company LyGenesis has initiated a phase II trial for its experimental therapy, LYG-LIV-001, which aims to grow miniature livers inside a person’s lymph nodes using hepatocytes derived from donated livers. The therapy could potentially offer a life-saving alternative for individuals with end-stage liver disease who are ineligible for conventional transplants. If successful, this regenerative medicine milestone could help address the imbalance between organ supply and demand, with the potential to treat many ESLD patients using a single donated liver. The trial, set to enroll 12 patients, is expected to conclude in early 2026, and the company is also exploring the use of its bioreactor technology to grow other organs.